ResApp (ASX:RAP) share price adds 4% on COVID-19 study rebate

The company's shares are continuing on yesterday's gains…

| More on:
Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResApp Health Ltd (ASX: RAP) share price is on the move again today following yesterday's meteoric rise. The digital health company provided another positive release to the ASX today.

At the time of writing, ResApp shares are fetching for 9.3 cents apiece, up 4.49%. It's worth noting that during early morning trade, its shares reached an intraday high of 10.2 cents.

ResApp secures rebate on COVID-19 study

Investors are pushing ResApp shares higher after the company secured a cashback for its COVID-19 research program.

According to the release, ResApp advised it has received approval from AusIndustry for its application for an Advanced and Overseas Finding. In particular, this is in relation to the expenditure associated with its COVID-19 clinical studies.

The finding covers the financial years between 2021 to 2023, meaning that ResApp will be eligible for a cash rebate. This refers to the company's COVID-19 overseas research and development expenditure, thus receiving a 43.5% cashback from the Australian government.

As such, ResApp estimates that it will collect a rebate of around $820,000 for the financial year that ended 30 June 2021.

In the United States, the company is currently recruiting participants for its upcoming pilot study. The aim is to collect data to train an algorithm in identifying COVID-19 through cough sounds recorded on a smartphone.

The same participants will also be used in a second study to collect further cough sounds and data on disease progression. ResApp hopes to develop algorithms to remotely monitor patients with COVID-19.

ResApp CEO and managing director, Dr Tony Keating commented:

Our COVID-19 research program is looking at developing algorithms for screening for COVID-19 as well as helping healthcare systems better manage patients with COVID-19, including those with long COVID. This finding, recognising the need to collect COVID-19 cough samples internationally, provides us with a high degree of certainty in planning our programs.

We are very grateful to the Federal Government for their commitment to supporting research and development by Australian companies.

ResApp share price summary

Until recently, ResApp shares were trading at multi-year lows, before shooting up in September. The past month alone has netted investors a return of more than 115%, however year-to-date, is up marginally at 14%.

ResApp commands a market capitalisation of about $83.3 million and has 859 million shares on its books.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Broker Notes

10 of the best ASX shares to buy in 2025

Analysts think these shares are in the buy zone for investors in 2025.

Read more »

Emotional euphoric young woman giving high five to male partner, celebrating family achievement, getting bank loan approval, or financial or investing success.
Share Gainers

Why Bowen Coal, Droneshield, Mesoblast, and St Barbara shares are racing higher today

These shares are ending the week positively. But why?

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Share Fallers

Why Cettire, Digico, KMD, and WiseTech shares are falling today

These shares are out of form on Friday. But why?

Read more »

Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys right now.

Read more »

Broker Notes

Brokers say these ASX growth stocks are top buys

Analysts have good things to say about these shares this month.

Read more »

Share Market News

Bell Potter names 2 of the best ASX 300 stocks to buy in 2025

These could be best buys next year according to the broker.

Read more »

A man looking at his laptop and thinking.
Share Market News

5 things to watch on the ASX 200 on Friday

On Tuesday, the S&P/ASX 200 Index (ASX: XJO) went into the Christmas break with a small gain. The benchmark index rose 0.25%…

Read more »

Hand holding Australian dollar (AUD) bills, symbolising ex dividend day. Passive income.
Broker Notes

Invest $1,000 into Pilbara Minerals and these ASX 200 stocks

Analysts have named these shares as top picks for a $1,000 investment. Let's see why.

Read more »